Pinato and colleagues1 found that antibiotic (ATB) therapy administered prior (pATB) to immune checkpoint inhibitor (ICI) therapy was associated with a worse overall survival (OS) in patients with cancer treated with ICI therapy. This finding would have important implications for ATB use prior to ICI therapy. However, in our opinion, the negative association of pATB with ICI efficacy was overestimated, and several problems and mistakes in the study may make the conclusion misleading and biased.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Huang X, Gao P, Wang Z. Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol. 2020;6(4):586–587. doi:10.1001/jamaoncol.2019.6859
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: